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CASE REPORT

Cache Valley Virus in a Patient Diagnosed with Aseptic Meningitis
Nang L. Nguyen,a Guoyan Zhao,b Rene Hull,c Mark A. Shelly,d Susan J. Wong,e Guang Wu,f Kirsten St. George,c David Wang,b,f
Marilyn A. Menegusa

Cache Valley virus was initially isolated from mosquitoes and had been linked to central nervous system-associated diseases. A
case of Cache Valley virus infection is described. The virus was cultured from a patient’s cerebrospinal fluid and identified with
real-time reverse transcription-PCR and sequencing, which also yielded the complete viral coding sequences.

CASE REPORT

I

n mid-September 2011, a 63-year-old woman presented to an
upstate New York hospital with complaints of fever, headache,
neck stiffness, and photophobia. One week earlier, she had noticed a macular, nonpruritic lesion on her right forearm, about 3
cm in diameter, with central clearing. Three days prior, as the first
lesion was fading, a petechial rash developed on her lower extremities that spread to her torso. She then traveled to Pennsylvania for
a weekend, and during this time she developed the mentioned
fever and symptoms of meningitis. She returned home and went
to the Emergency Department (ED) of the hospital the next
morning.
On physical examination, the patient appeared alert and oriented, with a blood pressure of 148-mm/80-mm Hg, a pulse rate
of 87 per min, a respiratory rate of 18 per min, an oral temperature
of 37.6°C, and an oxygen saturation of 99% on room air. She had
a scattered, bilateral, petechial rash on her thighs; meanwhile, the
lesions on her back and abdomen were fading. She had moderate
neck stiffness. Her neurologic exam was otherwise normal; there
was no evidence of encephalitis, cranial nerve abnormalities, or
focal findings.
Her medical record included a history of hypertension, hypothyroidism, meningioma, and migraine headaches and of rheumatic fever during childhood. The patient stated that she and her
husband frequently camped outdoors. Throughout mid- to late
August they camped in Wyoming and Livingston counties in New
York state and also embarked on a 5-day camping trip in Dansville, NY, through Vermont and New Hampshire. She lived with
her husband, had a cat, and frequently tended to her garden
around her home. She had no knowledge of any sick contact.
Her white blood cell count on presentation was 5,700/l, with
a normal differential. Hematocrit was normal at 42%, and platelets were normal at 212,000/l. Computed tomography of the
head without contrast showed mild atrophy without evidence of
acute intracranial abnormality. Blood cultures were drawn, and
she was sent home on doxycycline. The patient returned to the ED
the following day with new complaints of nausea and vomiting in
addition to the previously reported symptoms.
The patient was admitted to the hospital with a preliminary
diagnosis of aseptic meningitis. A lumbar puncture was performed, and the cerebrospinal fluid (CSF) showed 216 nucleated
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cells, with 91% lymphocytes, 7% monocytes, 1% basophils, and
1% polymorphonuclear cells. CSF chemistries were normal, with
a glucose concentration of 60 mg/dl (56% of the serum level) and
protein of 46 mg/dl. No microorganism was seen in the CSF by
Gram stain. Magnetic resonance imaging of the brain showed only
a small, stable meningioma. A virus culture of the CSF was initiated on several cell lines. PCR testing for enteroviruses in CSF and
for herpes simplex virus in blood and CSF was performed. Serologic tests to detect antibodies against Borrelia burgdorferi, Ehrlichia chaffeensis, Anaplasma phagocytophila, and Rickettsia (both
typhus and Rocky Mountain spotted fever) in blood were also
conducted. All molecular and serologic test results were negative.
Bacterial culture of the blood and CSF yielded no growth.
The patient gradually improved and was discharged 4 days
after admission to complete a 10 day-course of doxycycline at
home. On follow-up 2 months later, she reported transient difficulties in word finding that occurred soon after the hospital discharge and had resolved at the time of the visit. Her headaches,
including a migranous aura, were more severe following this hospitalization. She continued seeking medical care for her worsening
headaches and memory loss a year later.
Six days after inoculation of the CSF, a questionable cytopathic
effect (CPE) was noticed in the Buffalo green monkey kidney
(BGMK) cell culture. Other inoculated cell lines included rhesus
monkey kidney (RhMK) and human male fetal lung (MRC5);
both of these lines failed to produce any CPE. After three passages
in BGMK cells, the amplified supernatant was filtered and inoculated, and CPE was successfully produced in human colon adenocarcinoma (CaCo2), human lung carcinoma (A549), MRC5, and
an African green monkey kidney cell line (Vero). Characteristics
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of CPE involved initial cell rounding, followed by clumping and
sloughing off of the cell monolayer (Fig. 1). No CPE was observed
after the amplified stock was inoculated into RhMK cells, human
female fetal lung (WI-38) cells, or human embryonal rhabdomyosarcoma (RD) cells.
Cultured virus from day 2 postinoculation CaCo2 cells was
harvested, and nucleic acids were extracted using a QIAcube automated nucleic acid extractor (Qiagen, Germantown, MD). A
molecular panel for the detection of encephalitis viruses was performed on the extract (1). Included in this panel was a duplex
real-time reverse transcription-PCR (RT-PCR) for the detection
of Cache Valley virus (CVV) and the California serogroup viruses
(2). The sample tested positive for CVV in this assay. All other
PCR results were negative. For confirmation, cDNA was generated from the viral RNA using an iScript cDNA synthesis kit (BioRad, Hercules, CA) and a conventional PCR that targets the S
segment of the CVV genome (3). Sequence analysis of the 170nucleotide (nt) amplicon showed 100% identity with several
strains of CVV in GenBank.
To better characterize the CVV that infected the patient, the
virus genome was subjected to additional sequencing. Briefly, viral
RNAs were extracted, reverse transcribed, and PCR amplified with
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FIG 1 Cytopathic effect of the CVV-infected Vero cells. Vero cells were
seeded in a 24-well plate and grown to 90% confluence and were either
mock infected (A) or infected at a multiplicity of infection (MOI) of 0.3 (B)
or at an MOI of 30 (C) with the MNZ-92011 strain, which was harvested
from BGMK cells, amplified, and titrated in Vero cells. Photographs were
taken on day 4 postinfection, using a Spot RT-KE monochrome camera
connected to a Nikon Diaphot TMD microscope at ⫻40 magnification and
Spot 5.0 Basic software.

random primers. The PCR products were sequenced using a 454
GS-FLX Titanium platform (454 Life Sciences, Branford, CT),
yielding a total of 139,321 reads, of which 815 shared 60.4% to
100% identity to viruses in the family Bunyaviridae. All unknown
and Bunyavirus-like reads were then employed to assemble contigs via the supplied Newbler v.2.6 software. A single contig of 905
nt was constructed (⬎32⫻ coverage) that showed 99% identity
(99% coverage; E value, 0.0E ⫹ 00) with the S segment of 4 Yucatan strains of CVV (BLASTN version 2.2.27; the GenBank query
was performed on 21 August 2012). Five other contigs of length
138 to 2,164 nt were assembled and shared 92.5% to 97% identity with regions of the M segment of various CVV strains.
Fourteen contigs of length 110 to 3,014 nt were also generated,
sharing 71% to 100% identity with regions of the L segment of
Tensaw, Batai, and Ngari viruses as well as of the partially sequenced L segment of several CVV strains. Using targetedprimer RT-PCR followed by TOPO cloning and Sanger sequencing, we closed the gaps between the contigs and
confirmed partial sequences of 877 nt for the S segment, of
4,460 nt for the M segment, and of 6,871 nt for the L segment of
this CVV.
We next assessed seroconversion in a pair of patient sera
collected at the time of admission and at 24 days later. A neutralization assay in 24-well microplates was developed, using
the patient strain harvested from BGMK cells and then passaged twice through Vero cells. Briefly, test sera were serially
2-fold diluted in tissue culture medium, mixed with 100 50%
tissue culture infective doses (TCID50) of virus, incubated for 1
h at room temperature, and then added in duplicate onto the
Vero cell monolayers that were 90% confluent. The cells were
incubated in 5% CO2 at 37°C for 5 days, and CPE was monitored by microscopic inspection during the incubation period.
Complete protection of the cell monolayers was observed at or
below the 1:160 dilution with a positive-control serum, an antiCVV mouse hyperimmune serum (Centers for Disease Control
and Prevention, Fort Collins, CO), and at or below the 1:80
dilution with the patient convalescent-phase serum. In contrast, the acute-phase serum failed to neutralize the virus at all
tested dilutions, indicating that the patient was recently infected with CVV.
To confirm the neutralization data, an immunofluorescence
assay (IFA) was established to detect CVV-specific antibodies.
Briefly, the BGMK cell-derived virus was used to inoculate CaCo2
cells, which were harvested at moderate CPE and used to produce
slides for the IFA. Cells were trypsinized, washed, and resuspended in tissue culture medium; cell spots were then air dried
and fixed in cold acetone for 30 min. Control slides were prepared
in the same fashion with mock-infected CaCo2 cells. CVV-infected CaCo2 cells were incubated with the patient’s 24-day convalescent-phase serum at dilutions ranging from 1:16 to 1:4,096.
To demonstrate specificity, CVV-infected CaCo2 cells were also
incubated with an anti-CVV mouse serum, an anti-La Crosse encephalitis virus human serum (Wadsworth Center, Albany, NY),
and a negative-control human serum (Focus Diagnostics, Cypress, CA), all at the same dilutions. All described antisera were
also tested in parallel at a dilution of 1:16 on control slides. Slides
that contained the patient convalescent and anti-CVV mouse sera
were reactive, with a titer of 1:1,024 (Fig. 2). Neither the negativecontrol human serum (data not shown) nor the anti-La Crosse
virus human serum was reactive to the CVV-infected cells (⬍1:
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16). On control slides of mock-infected cells, no CVV-specific
staining pattern was observed, validating the test results for the
CVV-infected cells.

Cache Valley virus is a negative-sense, single-stranded RNA
virus with a tripartite genome. It belongs to the Bunyamwera serogroup in the genus Orthobunyavirus and was named after the
location in northern Utah where it was first isolated from mosquitoes (4). The virus has since been found to be widespread in North
and Central America, infecting many species of domestic and wild
animals such as deer, cattle, sheep, and horses (5, 6, 7, 8). Epidemiologic studies indicate that CVV can be transmitted via a broad
range of mosquito species (9), with the white-tailed deer population as a potential natural reservoir (10).
CVV is a concern in animal husbandry due to its ability to
cause abortion, stillbirth, and congenital defects of the musculoskeletal and central nervous systems in affected ruminants (11,
12). In humans, CVV disease was first identified in a previously
healthy young man from North Carolina following a deer-hunting trip (13). Subsequently, a case of aseptic meningitis due to
CVV in an adult male from Wisconsin was reported (14). Other
human infections with CVV have been inferred by serologic studies of CVV in areas of endemicity in the Delmarva Peninsula in the
United States and in Yucatan, Mexico, with reported infection
rates of up to 18% (15, 16).
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We describe here a case of CVV disease in a human. Similar to
the Wisconsin case, this virus was isolated from the patient’s
acute-phase CSF. Its positive identification was made via a laboratory-developed real-time RT-PCR, followed by genomic sequencing. We also demonstrated that the anti-CVV antibody titer
of a convalescent-phase serum had risen sharply compared to the
titer of an acute-phase serum drawn 3 weeks earlier, indicating
that the CVV infection had just been acquired. In the absence of
other etiology and coupled with previous observations that CVV
infection can lead to central nervous system (CNS)-associated diseases, it is reasonable to conclude that CVV was responsible for
this patient’s illness. Due to the lack of molecular epidemiology of
CVV in regions where the patient traveled, however, it was not
possible to determine the time and place of her exposure.
Segmented RNA viruses can evolve over time through genomic
reassortment. This characteristic has been reported in members of
the Bunyamwera serogroup, including CVV (17). Through the
effort to identify the CVV strain involved, we obtained a sequence
of 877 nt of the virus S segment, containing two open reading
frames (ORF) of 233 and 101 amino acids (aa). Their translated
sequences possessed 100% identity to the deduced N and NSs
proteins, respectively, of 5 CVV mosquito isolates previously collected in the Yucatan area (18). We also sequenced 4,460 nt of the
virus M segment, which encodes a hypothetical polyprotein precursor of 1,434 aa. This polyprotein shares at most 94% nucleotide
identity and 98% amino acid identity with its homologues in 7
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FIG 2 Detection of anti-CVV antibodies in the patient’s convalescent-phase serum. The results of an IFA of the patient’s 24-day convalescent-phase serum (I),
an anti-CVV mouse hyperimmune serum (II), and an anti-La Crosse virus human convalescent-phase serum (III), using Caco2 cells that were mock infected (BI
to BIII) or at day 2 postinfection with the MNZ-92011 strain (AI to AIII), are shown. Fluorescein isothiocyanate (FITC)-conjugated dual anti-human/anti-mouse
IgG goat antibody (Focus Diagnostics, Cypress, CA) was used as a secondary antibody. Images were taken with a Zeiss AxioCam MRc camera attached to
AxioImager A1 microscope at ⫻400 magnification, using Zeiss AxioVision 3.1 software. All sera were at a dilution of 1:16, with the exception of the anti-CVV
mouse serum represented in panels AII and BII, where the serum was diluted 1:1,024.
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CVV strains isolated in North America (see Fig. S1 and Table S1 in
the supplemental material). In addition, we deciphered the majority (6,871 nt) of the virus L segment. It contains an ORF for a
protein of 2,228 aa which shows 88% and 83% aa identity with the
predicted RNA-dependent RNA polymerase of Tensaw and Batai
viruses, respectively. At present, no complete ORF encoding the
predicted RNA polymerase of CVV exists in GenBank. This report
thus provides full nucleotide sequence coverage for this protein.
In conclusion, we report a confirmed case of meningitis due to
CVV infection. Since the discovery of CVV over half a century ago,
there have been surprisingly few human cases reported. Given the
wide geographic distribution of CVV and its transmission via a
large number of mosquito species, we suspect that CVV infection
is underreported. A targeted study may be needed to assess the
true scope of human infection with this virus. Additionally, inclusion of CVV in routine arbovirus surveillance is suggested. Knowledge of the areas of CVV endemicity might benefit clinicians in the
differential diagnoses of CNS-related diseases. And, finally, this
study reports complete coding sequences of a CVV, including the
L segment-encoded RNA polymerase.
Nucleotide sequence accession numbers. The sequenced L,
M, and S segments of this CVV (MNZ-92011 strain) have been
deposited in GenBank under accession numbers KC436106,
KC436107, and KC436108, respectively.

